Comparative Pharmacology
Head-to-head clinical analysis: MENTAX versus OXICONAZOLE NITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MENTAX versus OXICONAZOLE NITRATE.
MENTAX vs OXICONAZOLE NITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal squalene epoxidase, thereby blocking ergosterol biosynthesis and causing accumulation of squalene, leading to fungal cell death.
Oxiconazole nitrate is an azole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, by inhibiting the enzyme lanosterol 14α-demethylase. This leads to increased membrane permeability and cell death.
Butenafine hydrochloride 1% cream: apply to affected area once daily for 2 weeks for tinea pedis; for tinea corporis and tinea cruris, apply once daily for 1 week.
Apply a thin layer to affected skin once daily for 2 weeks for tinea pedis, tinea cruris, and tinea corporis.
None Documented
None Documented
Terminal elimination half-life is approximately 5-6 hours; clinical significance: supports twice-daily dosing for topical antifungal therapy.
Terminal elimination half-life is approximately 20-30 hours, allowing once-daily or twice-daily topical application.
Primarily fecal (biliary) as unchanged drug and metabolites; renal excretion of metabolites accounts for less than 1% of the dose.
Primarily biliary/fecal: >75% of dose excreted unchanged and as metabolites in feces via bile; renal excretion accounts for <10% (mostly inactive metabolites).
Category C
Category C
Topical Antifungal
Topical Antifungal